CG Capital Markets Says Buy Oxford Nanopore

Canaccord Genuity have rated Oxford Nanopore a buy with a target price of 180 pence (not 180 pounds as reported by GenomeWeb).

The CG thesis around this may or may not be right, but it contains a number of errors and omissions.

“enhanced throughput to 290 gigabases (Gb) per flow cell by improving its hardware (developing PromethION) over time.”

In general I felt that CG took Oxford statements at face value, without providing much of a critical analysis. This is one example, where they quote the “maximum theoretical output” of the device. You might as well quote 19.4Tb for a PacBio run as quote this number. Making PacBio 100x more attractive than Oxford…